Trial Profile
A Retrospective Study Evaluating the Bone Scan Index (BSI) as a Prognostic Biomarker for Overall Survival (OS) in Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC )Patients Treated with Radium-223 (Ra-223)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 15 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium.